A phase III clinical trial of GC1111 as an enzyme replacement therapy in previously untreated mucopolysaccharidosis type II (Hunter syndrome) patients: A double-blind, randomized, activecontrolled (part 1) and open-labeled, historical placebocontrolled (part 2) study